157 related articles for article (PubMed ID: 31227048)
1. Molecular Imaging and Theranostics-A Multidisciplinary Approach.
Farolfi A; Lima GM; Oyen W; Fanti S
Semin Nucl Med; 2019 Jul; 49(4):247-254. PubMed ID: 31227048
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
5. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
Gorin MA; Rowe SP; Denmeade SR
PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
[TBL] [Abstract][Full Text] [Related]
6. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
7. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
8. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
[No Abstract] [Full Text] [Related]
9. Consensus on molecular imaging and theranostics in prostate cancer.
Fanti S; Minozzi S; Antoch G; Banks I; Briganti A; Carrio I; Chiti A; Clarke N; Eiber M; De Bono J; Fizazi K; Gillessen S; Gledhill S; Haberkorn U; Herrmann K; Hicks RJ; Lecouvet F; Montironi R; Ost P; O'Sullivan JM; Padhani AR; Schalken JA; Scher HI; Tombal B; van Moorselaar RJA; Van Poppel H; Vargas HA; Walz J; Weber WA; Wester HJ; Oyen WJG
Lancet Oncol; 2018 Dec; 19(12):e696-e708. PubMed ID: 30507436
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
11. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
12. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
Kilcoyne A; Harisinghani MG; Mahmood U
J Nucl Med; 2016 Oct; 57(Suppl 3):105S-110S. PubMed ID: 27694162
[TBL] [Abstract][Full Text] [Related]
14. New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.
Afaq A; Batura D; Bomanji J
Int Urol Nephrol; 2017 May; 49(5):803-810. PubMed ID: 28197764
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
16. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer.
Meyer AR; Joice GA; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Nov; 28(6):493-498. PubMed ID: 30188333
[TBL] [Abstract][Full Text] [Related]
17. Molecular Imaging for Primary Staging of Prostate Cancer.
Pomykala KL; Farolfi A; Hadaschik B; Fendler WP; Herrmann K
Semin Nucl Med; 2019 Jul; 49(4):271-279. PubMed ID: 31227050
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
19. The timing of molecular imaging in prostate cancer.
Morris MJ
Clin Adv Hematol Oncol; 2018 Mar; 16(3):195-197. PubMed ID: 29742075
[No Abstract] [Full Text] [Related]
20. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
